GSK plc announced that the U.S. Food and Drug Administration has extended the approved indication for its RSV vaccine, Arexvy, to cover adults aged 18 to 49 years who are at increased risk for lower respiratory tract disease caused by respiratory syncytial virus. The vaccine had already been cleared in the United States for adults 60 and older, and for those aged 50 to 59 who face elevated risk of severe RSV illness.
Public health survey data cited by GSK indicate an estimated 21 million U.S. adults under 50 carry at least one condition that predisposes them to serious RSV infection. That estimate is derived from the National Health and Nutrition Examination Survey and reflects that about 17% of adults aged 20 to 49 reported at least one qualifying risk factor. The conditions listed include congestive heart failure, coronary heart disease, stroke, chronic obstructive pulmonary disease, asthma, diabetes, liver disease, and renal disease.
The burden of RSV among adults ages 18 to 49 in the U.S. is notable: the company cited a systematic review and meta-analysis of studies spanning 2007 to 2021 that estimated roughly 17,000 hospitalisations, 277,000 emergency department visits, and 1.97 million outpatient visits annually in this age group. According to the same study, most hospitalisations among younger adults occur in those who have chronic medical conditions that increase their risk for severe RSV disease.
The FDA’s expanded approval relied on evidence from a Phase IIIb trial that showed Arexvy elicited an immune response in 18 to 49 year-olds that was non-inferior to the response seen in adults aged 60 and above. GSK said the safety profile observed in the Phase IIIb trial aligned with results from its broader Phase III programme that underpinned the vaccine’s initial U.S. approval. The most frequently reported adverse events within four days of vaccination were injection site pain, fatigue, myalgia, headache, and arthralgia.
The Phase IIIb study enrolled 1,458 participants across 52 locations in six countries, including 16 sites in the United States. It specifically compared the immune responses of participants aged 18 to 49 who had pre-defined stable chronic diseases that confer increased risk for RSV disease to those of adults aged 60 years and older.
Key points
- FDA has expanded Arexvy’s U.S. indication to include high-risk adults aged 18-49, adding to prior approvals for older age groups.
- GSK cites an estimated 21 million U.S. adults under 50 with at least one risk factor for severe RSV, based on NHANES data indicating 17% prevalence in ages 20-49.
- Estimated annual RSV burden for U.S. adults 18-49 includes about 17,000 hospitalisations, 277,000 emergency visits, and nearly 2 million outpatient visits, concentrated among those with chronic conditions.
Risks and uncertainties
- Safety considerations: Common adverse events reported within four days of vaccination include injection site pain, fatigue, myalgia, headache, and arthralgia, which could affect uptake and monitoring in clinical settings - impacting healthcare delivery and public health administration.
- Burden concentration: Most hospitalisations among younger adults were reported in those with chronic medical conditions, indicating the expanded indication targets a specific subpopulation - relevant for vaccine deployment strategies and healthcare resource planning.
- Regulatory basis: The FDA’s decision was supported by Phase IIIb data showing a non-inferior immune response compared to older adults; the approval relied on immunogenicity evidence from a trial of 1,458 participants across multiple countries and sites, which is material to continued post-marketing surveillance and evaluation.
GSK’s expanded approval marks a regulatory step to address RSV risk in younger adults with pre-existing medical conditions, and it frames where clinical demand and healthcare impacts are most likely to concentrate.